CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Tecentriq for Non-Small Cell Lung Cancer – Details

Project Number PC0115-000
Brand Name Tecentriq
Generic Name Atezolizumab
Strength 60 mg/mL
Tumour Type Lung
Indication Non-Small Cell Lung Cancer
Funding Request For the treatment of patients with locally advanced or metastatic non-small cell lung cancer who have progressed on or after systemic chemotherapy until loss of clinical benefit
Review Status Complete
Pre Noc Submission Yes
NOC Date April 6, 2018
Manufacturer Hoffmann-La Roche Limited
Sponsor Hoffmann-La Roche Limited
Submission Date December 15, 2017
Submission Deemed Complete December 22, 2017
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ January 8, 2018
Check-point meeting February 13, 2018
pERC Meeting May 17, 2018
Initial Recommendation Issued June 1, 2018
Feedback Deadline ‡ June 15, 2018
Final Recommendation Issued June 20, 2018
Notification to Implement Issued July 6, 2018
Therapeutic Area Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.